10,006 Shares in Zoetis Inc. $ZTS Bought by RNC Capital Management LLC

Key Points

• RNC Capital Management purchased a new position of 10,006 shares of Zoetis in Q4, valued at about $1.26 million, and institutional investors now own roughly 92.8% of the stock.
• Zoetis beat quarterly expectations with EPS of $1.48 versus $1.40 and revenue of $2.39B, and set FY2026 guidance of 7.00–7.10 EPS (analysts forecast ~7.01).
• The company declared a quarterly dividend of $0.53 ($2.12 annualized, 1.9% yield); the stock trades near $112.81 with a $47.45B market cap and a consensus analyst rating of Hold (price target $151.75).

RNC Capital Management LLC purchased a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 10,006 shares of the company's stock, valued at approximately $1,259,000.

Other hedge funds have also recently made changes to their positions in the company. Sun Financial Inc purchased a new position in shares of Zoetis in the fourth quarter valued at $295,000. KPP Advisory Services LLC increased its stake in Zoetis by 3.7% in the 4th quarter. KPP Advisory Services LLC now owns 7,567 shares of the company's stock worth $952,000 after acquiring an additional 272 shares during the last quarter. Intact Investment Management Inc. bought a new position in Zoetis in the 4th quarter worth about $75,000. Legacy Edge Advisors LLC bought a new position in Zoetis in the 4th quarter worth about $246,000. Finally, Strs Ohio increased its stake in Zoetis by 3.1% in the 4th quarter. Strs Ohio now owns 162,124 shares of the company's stock worth $20,398,000 after acquiring an additional 4,927 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

ZTS opened at $112.81 on Tuesday. The stock has a 50-day moving average price of $119.93 and a 200-day moving average price of $124.53. Zoetis Inc. has a 12-month low of $112.10 and a 12-month high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a market capitalization of $47.45 billion, a P/E ratio of 18.74, a PEG ratio of 1.76 and a beta of 0.87.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion during the quarter, compared to analysts' expectations of $2.36 billion. During the same period in the prior year, the business earned $1.40 EPS. The company's revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts predict that Zoetis Inc. will post 7.01 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Monday, April 20th. Zoetis's dividend payout ratio is presently 35.22%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Leerink Partners restated a "market perform" rating on shares of Zoetis in a research note on Tuesday, March 10th. Piper Sandler restated a "neutral" rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Wall Street Zen lowered Zoetis from a "buy" rating to a "hold" rating in a research note on Saturday. Bank of America upped their target price on Zoetis from $135.00 to $140.00 and gave the stock a "neutral" rating in a research note on Friday, February 13th. Finally, William Blair restated an "outperform" rating on shares of Zoetis in a research note on Monday, March 2nd. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Zoetis has an average rating of "Hold" and a consensus price target of $151.75.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.